Research ArticleOriginal Article
Open Access

Invasive Candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia

A 5-year retrospective study

Zainab Almoosa, Gasmelseed Y. Ahmed, Abeer Omran, Ayah AlSarheed, Afnan Alturki, Abdulaziz Alaqeel, Mohammed Alshehri, Tariq Alfawaz and Dayel Alshahrani
Saudi Medical Journal November 2017, 38 (11) 1118-1124; DOI: https://doi.org/10.15537/smj.2017.11.21116

References

  1. ↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes D,
    4. Benjamin DK Jr.,
    5. Calandra TF,
    6. Edwards JE Jr.,
    7. et al.
    (2009) Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Al Thaqafi AH,
    2. Farahat FM,
    3. Al Harbi MI,
    4. Al Amri AF,
    5. Perfect JR
    (2014) Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, Western Saudi Arabia. Int J Infect Dis 21:5–9.
    OpenUrlCrossRef
  3. ↵
    1. Delaloye J,
    2. Calandra T
    (2014) Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5:161–169.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Dornbusch HJ,
    2. Manzoni P,
    3. Roilides E,
    4. Walsh TJ,
    5. Groll AH
    (2009) Invasive fungal infections in children. Pediatr Infect Dis J 28:734–737.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Pfaller MA,
    2. Andes DR,
    3. Diekema DJ,
    4. Horn DL,
    5. Reboli AC,
    6. Rotstein C,
    7. et al.
    (2014) Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 9:e101510.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Alothman AF,
    2. Al-Musawi T,
    3. Al-Abdely HM,
    4. Salman JA,
    5. Almaslamani M,
    6. Yared N,
    7. et al.
    (2014) Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: Expert panel recommendations. J Infect Public Health 7:6–19.
    OpenUrlCrossRefPubMed
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes DR,
    4. Clancy CJ,
    5. Marr KA,
    6. Ostrosky-Zeichner L,
    7. et al.
    (2016) Clinical Practice Guideline for the Management of Candidiasis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50.
    OpenUrlCrossRefPubMed
    1. Cornely OA,
    2. Bassetti M,
    3. Calandra T,
    4. Garbino J,
    5. Kullberg BJ,
    6. Lortholary O,
    7. et al.
    (2012) ESCMID*guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37.
    OpenUrlCrossRefPubMed
    1. Ullmann AJ,
    2. Akova M,
    3. Herbrecht R,
    4. Viscoli C,
    5. Arendrup MC,
    6. Arikan-Akdagli S,
    7. et al.
    (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67.
    OpenUrlCrossRefPubMed
    1. Bow EJ,
    2. Evans G,
    3. Fuller J,
    4. Laverdière M,
    5. Rotstein C,
    6. Rennie R,
    7. et al.
    (2010) Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol 21:e122–e150.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Hope WW,
    2. Castagnola E,
    3. Groll AH,
    4. Roilides E,
    5. Akova M,
    6. Arendrup MC,
    7. et al.
    (2012) ESCMID*guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18:38–52.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gudlaugsson O,
    2. Gillespie S,
    3. Lee K,
    4. Vande Berg J,
    5. Hu J,
    6. Messer S,
    7. et al.
    (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177.
    OpenUrlCrossRefPubMedWeb of Science
    1. Garey KW,
    2. Rege M,
    3. Pai MP,
    4. Mingo DE,
    5. Suda KJ,
    6. Turpin RS,
    7. et al.
    (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31.
    OpenUrlCrossRefPubMedWeb of Science
    1. Fraser A,
    2. Paul M,
    3. Almanasreh N,
    4. Tacconelli E,
    5. Frank U,
    6. Cauda R,
    7. et al.
    (2006) Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119:970–976.
    OpenUrlCrossRefPubMedWeb of Science
    1. Morrell M,
    2. Fraser VJ,
    3. Kollef MH
    (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Kollef M,
    2. Micek S,
    3. Hampton N,
    4. Doherty JA,
    5. Kumar A
    (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739–1746.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Steinbach WJ,
    2. Roilides E,
    3. Berman D,
    4. Hoffman JA,
    5. Groll AH,
    6. Bin-Hussain I,
    7. et al.
    (2012) Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 31:1252–1257.
    OpenUrlCrossRefPubMed
    1. Santolaya ME,
    2. Alvarado T,
    3. Queiroz-Telles F,
    4. Colombo AL,
    5. Zurita J,
    6. Tiraboschi IN,
    7. et al.
    (2014) Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J 33:e40–e44.
    OpenUrl
  19. ↵
    1. Pemán J,
    2. Cantón E,
    3. Linares-Sicilia MJ,
    4. Roselló EM,
    5. Borrell N,
    6. Ruiz-Pérez-de-Pipaon MT,
    7. et al.
    (2011) Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol 49:4158–4163.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Clinical and Laboratory Standards Institute
    (2012) Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts. Informational supplement, CLSI document M27-S3 (Clinical and Laboratory Standards Institute, Wayne (USA)).
  21. ↵
    1. Sievert DM,
    2. Ricks P,
    3. Edwards JR,
    4. Schneider A,
    5. Patel J,
    6. Srinivasan A,
    7. et al.
    (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1–14.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wisplinghoff H,
    2. Seifert H,
    3. Tallent SM,
    4. Bischoff T,
    5. Wenzel RP,
    6. Edmond MB
    (2003) Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 22:686–691.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Watson RS,
    2. Carcillo JA,
    3. Linde-Zwirble WT,
    4. Clermont G,
    5. Lidicker J,
    6. Angus DC
    (2003) The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 167:695–701.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Creutzig U,
    2. Zimmermann M,
    3. Reinhardt D,
    4. Dworzak M,
    5. Stary J,
    6. Lehrnbecher T
    (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Pagano L,
    2. Caira M,
    3. Candoni A,
    4. Offidani M,
    5. Fianchi L,
    6. Martino B,
    7. et al.
    (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Martin SR,
    2. Atkison P,
    3. Anand R,
    4. Lindblad AS
    (2004) Studies of pediatric liver transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant 8:273–283.
    OpenUrlPubMed
  27. ↵
    1. Profumo RJ
    (2006) Pediatric liver transplant recipients: mortality analysis over 20 years. J Insur Med 38:3–8.
    OpenUrlPubMed
  28. ↵
    1. Zaoutis TE,
    2. Argon J,
    3. Chu J,
    4. Berlin JA,
    5. Walsh TJ,
    6. Feudtner C
    (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232–1239.
    OpenUrlCrossRefPubMedWeb of Science
    1. Pfaller MA,
    2. Diekema DJ,
    3. Jones RN,
    4. Messer SA,
    5. Hollis RJ
    (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 40:852–856.
    OpenUrlAbstract/FREE Full Text
    1. Krcmery V,
    2. Laho L,
    3. Huttova M,
    4. Ondrusova A,
    5. Kralinsky K,
    6. Pevalova L,
    7. et al.
    (2002) Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol 51:110–116.
    OpenUrlPubMedWeb of Science
    1. Hope WW,
    2. Seibel NL,
    3. Schwartz CL,
    4. Arrieta A,
    5. Flynn P,
    6. Shad A,
    7. et al.
    (2007) Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51:3714–3719.
    OpenUrlAbstract/FREE Full Text
    1. Blyth CC,
    2. Chen SC,
    3. Slavin MA,
    4. Serena C,
    5. Nguyen Q,
    6. Marriott D,
    7. et al.
    (2009) Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 123:1360–1368.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Zaoutis TE,
    2. Coffin SE,
    3. Chu JH,
    4. Heydon K,
    5. Zhao H,
    6. Greves HM,
    7. et al.
    (2005) Risk factors for mortality in children with candidemia. Pediatr Infect Dis J 24:736–739.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Singhi SC,
    2. Reddy TC,
    3. Chakrabarti A
    (2004) Candidemia in a pediatric intensive care unit. Pediatr Crit Care Med 5:369–374.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Zaoutis TE,
    2. Prasad PA,
    3. Localio AR,
    4. Coffin SE,
    5. Bell LM,
    6. Walsh TJ,
    7. et al.
    (2010) Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 51:e38–e45.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Palazzi DL,
    2. Arrieta A,
    3. Castagnola E,
    4. Halasa N,
    5. Hubbard S,
    6. Brozovich AA,
    7. et al.
    (2014) Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 33:1294–1296.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Dutta A,
    2. Palazzi DL
    (2011) Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 30:664–668.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Omrani AS,
    2. Makkawy EA,
    3. Baig K,
    4. Baredhwan AA,
    5. Almuthree SA,
    6. Elkhizzi NA,
    7. et al.
    (2014) Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J 35:821–826.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section